SG Americas Securities LLC Makes New $51,000 Investment in OptimizeRx Co. (NASDAQ:OPRX)

SG Americas Securities LLC acquired a new position in shares of OptimizeRx Co. (NASDAQ:OPRX) during the 4th quarter, Holdings Channel.com reports. The fund acquired 10,555 shares of the company’s stock, valued at approximately $51,000.

Several other large investors have also recently added to or reduced their stakes in OPRX. Rice Hall James & Associates LLC grew its stake in OptimizeRx by 24.0% during the third quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company’s stock worth $4,751,000 after buying an additional 119,306 shares during the last quarter. Janney Montgomery Scott LLC bought a new stake in OptimizeRx during the third quarter worth about $810,000. Bullseye Asset Management LLC grew its stake in OptimizeRx by 55.6% during the third quarter. Bullseye Asset Management LLC now owns 214,046 shares of the company’s stock worth $1,652,000 after buying an additional 76,458 shares during the last quarter. Barclays PLC grew its stake in OptimizeRx by 358.5% during the third quarter. Barclays PLC now owns 26,934 shares of the company’s stock worth $208,000 after buying an additional 21,060 shares during the last quarter. Finally, Quest Partners LLC grew its stake in OptimizeRx by 15,965.6% during the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after buying an additional 9,739 shares during the last quarter. 76.47% of the stock is owned by institutional investors.

OptimizeRx Trading Up 12.5 %

Shares of NASDAQ OPRX opened at $6.29 on Friday. The company’s 50 day simple moving average is $5.28 and its 200 day simple moving average is $6.42. OptimizeRx Co. has a fifty-two week low of $3.78 and a fifty-two week high of $16.65. The firm has a market capitalization of $115.86 million, a P/E ratio of -4.73 and a beta of 1.38. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.23 and a quick ratio of 3.23.

Analyst Ratings Changes

Several analysts have weighed in on OPRX shares. William Blair reaffirmed an “outperform” rating on shares of OptimizeRx in a research note on Thursday, November 14th. Stifel Nicolaus decreased their price target on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. Stephens initiated coverage on shares of OptimizeRx in a research note on Friday, December 20th. They set an “equal weight” rating and a $5.50 price target on the stock. Roth Mkm reissued a “buy” rating and set a $16.00 price target (down from $20.00) on shares of OptimizeRx in a research note on Thursday, November 14th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $6.00 price target (down from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, OptimizeRx currently has an average rating of “Moderate Buy” and a consensus price target of $9.06.

Insider Activity at OptimizeRx

In other OptimizeRx news, CEO William J. Febbo acquired 20,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $5.01 per share, for a total transaction of $100,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 601,253 shares of the company’s stock, valued at approximately $3,012,277.53. This represents a 3.44 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.10% of the stock is currently owned by company insiders.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.